Profile data is unavailable for this security.
About the company
ADVICENNE S.A. is a late-stage biopharmaceutical company based in France. The Company focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
- Revenue in EUR (TTM)2.94m
- Net income in EUR-7.03m
- Incorporated2007
- Employees20.00
- LocationAdvicenne SA21 allee Boissy d AnglasNIMES 30000FranceFRA
- Phone+33 466055420
- Fax+33 466212335
- Websitehttps://advicenne.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NicOx SA | 3.57m | -17.36m | 16.98m | 11.00 | -- | 0.3698 | -- | 4.75 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
| Phaxiam Therapeutics SA | 1.33m | -23.49m | 18.19m | 51.00 | -- | 0.7104 | -- | 13.72 | -5.56 | -5.56 | 0.3139 | 4.22 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| SMAIO SA | 7.62m | 1.06m | 19.97m | 37.00 | 18.75 | 1.84 | 8.39 | 2.62 | 0.2038 | 0.2038 | 1.46 | 2.07 | 0.5624 | 0.1871 | 17.23 | 206,027.60 | 7.81 | -7.87 | 10.24 | -19.76 | 96.95 | 96.04 | 13.89 | -22.48 | 2.54 | 11.07 | 0.1991 | -- | 212.18 | 114.99 | -62.80 | -- | -- | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 22.56m | 22.00 | -- | 5.59 | -- | 21.04 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Nfl Biosciences SAS | 0.00 | -3.48m | 23.63m | 3.00 | -- | 5.94 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
| Predilife SA | 317.79k | -4.22m | 24.93m | 19.00 | -- | -- | -- | 78.43 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Poxel SA | 1.55m | -44.24m | 29.50m | 30.00 | -- | -- | -- | 19.08 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
| Fermentalg SA | 4.06m | -14.15m | 31.62m | 62.00 | -- | 0.9698 | -- | 7.79 | -0.3176 | -0.3176 | 0.0917 | 0.6033 | 0.0753 | 0.533 | 3.35 | 65,451.61 | -24.63 | -21.94 | -26.79 | -24.71 | 13.21 | 14.73 | -327.08 | -248.95 | 3.53 | -60.94 | 0.3323 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
| Advicenne SA | 2.94m | -7.03m | 33.89m | 20.00 | -- | -- | -- | 11.52 | -0.6728 | -0.6728 | 0.2805 | -0.9746 | 0.2207 | 4.41 | 2.22 | 147,100.00 | -52.73 | -57.86 | -129.08 | -89.10 | -104.21 | -327.56 | -238.99 | -513.56 | 0.9196 | -18.36 | 3.19 | -- | 25.67 | 25.03 | 38.70 | -- | 55.28 | -- |
| Global Bioenergies SA | 3.25m | -8.66m | 35.92m | 46.00 | -- | 3.45 | -- | 11.05 | -0.4797 | -0.4797 | 0.1802 | 0.5743 | 0.1632 | 5.21 | 65.62 | 70,638.05 | -43.47 | -43.66 | -64.54 | -82.47 | -153.20 | -948.35 | -266.41 | -1,331.36 | 3.54 | -- | 0.2626 | -- | 365.83 | 36.25 | 27.78 | -- | -19.49 | -- |
| Gensight Biologics SA | 1.27m | -26.22m | 36.98m | 16.00 | -- | -- | -- | 29.19 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| genOway SA | 18.63m | 1.59m | 38.86m | 124.00 | 23.10 | 2.28 | 9.69 | 2.09 | 0.1814 | 0.1814 | 2.12 | 1.84 | 0.5813 | 0.3881 | 2.50 | 142,180.80 | 4.98 | -0.5615 | 6.72 | -0.8058 | 97.61 | 93.72 | 8.56 | -1.12 | 2.10 | 17.42 | 0.3344 | -- | 21.64 | 11.57 | 341.09 | -16.63 | -18.02 | -- |
| Abionyx Pharma SA | 4.64m | -3.52m | 40.57m | 61.00 | -- | 5.08 | -- | 8.74 | -0.121 | -0.121 | 0.1581 | 0.246 | 0.3027 | 21.86 | 4.20 | 76,694.22 | -22.95 | -18.82 | -32.52 | -28.87 | 13.32 | 14.32 | -75.82 | -128.54 | 1.70 | -- | 0.2997 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
| Groupe Berkem SA | 51.94m | 367.00k | 40.87m | 200.00 | 111.38 | 1.46 | 9.19 | 0.7867 | 0.0207 | 0.0207 | 2.92 | 1.57 | -- | -- | -- | 259,720.00 | -- | -- | -- | -- | 55.32 | -- | 0.7065 | -- | 0.8988 | 1.36 | 0.5798 | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| Biosynex SA | 93.05m | -13.79m | 40.87m | 560.00 | -- | -- | -- | 0.4392 | -1.94 | -1.94 | -- | -- | -- | -- | -- | 248,141.30 | -- | 25.60 | -- | 33.90 | 25.22 | 51.82 | -13.15 | 20.26 | -- | -4.45 | -- | 14.72 | -48.61 | 45.12 | -84.99 | 118.26 | -- | -- |
| AbL Diagnostics SA | 11.19m | 1.20m | 48.99m | 19.00 | 77.47 | 7.30 | 161.45 | 4.38 | 0.0392 | 0.0392 | 0.483 | 0.4165 | 1.18 | -- | 5.21 | 588,990.50 | 12.67 | 8.99 | 26.09 | 10.77 | 35.76 | 38.29 | 10.75 | 31.17 | 1.28 | -- | 0.31 | 0.00 | -- | 67.89 | 328.77 | -- | 43.20 | -- |
Data as of Jun 07 2024. Currency figures normalised to Advicenne SA's reporting currency: Euro EUR
1.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mandarine Gestion SAas of 29 Feb 2024 | 180.00k | 1.46% |
| Friedland Gestion SASas of 26 Jan 2024 | 3.75k | 0.03% |
Data from 31 Jan 2024 - 29 Feb 2024Source: FactSet Research Systems Inc.
